Eleven Biotherapeutics (EBIO) Appoints Wendy L. Dixon, PhD To Board Of Directors

Eleven Biotherapeutics (EBIO) Appoints Wendy L. Dixon, PhD To Board Of Directors

Eleven Biotherapeutics, a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced the appointment of industry veteran Wendy L. Dixon, PhD, former Chief Marketing Officer and President of Global Marketing for Bristol Myers Squibb, to the company's Board of Directors.